Halozyme Therapeutics (HALO) Non-Current Debt (2012 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Non-Current Debt of $1.9 billion for Q1 2026, up 28.42% year-over-year from $1.5 billion in Q1 2025, and down 9.65% quarter-over-quarter from $2.1 billion in Q4 2025.
Halozyme Therapeutics (HALO) Non-Current Debt (2012 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Non-Current Debt for 15 consecutive years, with $1.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 28.42% year-over-year to $1.9 billion; the TTM figure through Mar 2026 stood at $1.9 billion (up 28.42% YoY), while the FY2025 annual figure was $2.1 billion, up 42.29% from the prior year.
- Non-Current Debt fell to $1.9 billion in Q1 2026 per HALO's latest filing, from $2.1 billion in the prior quarter.
- Across five years, Non-Current Debt topped out at $2.1 billion in Q4 2025 and bottomed at $788.1 million in Q1 2022.
- Historically, Non-Current Debt has averaged $1.5 billion across 5 years, with a median of $1.5 billion in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Debt surged 91.31% — and 2025, when it tumbled 46.81%.
- Halozyme Therapeutics' Non-Current Debt stood at $1.5 billion in 2022, then decreased by 0.45% to $1.5 billion in 2023, then increased by 0.44% to $1.5 billion in 2024, then surged by 42.29% to $2.1 billion in 2025, then retreated by 9.65% to $1.9 billion in 2026.
- Business Quant data shows HALO's Non-Current Debt at $1.9 billion in Q1 2026, $2.1 billion in Q4 2025, and $800.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 1.94 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.94 Bn |
| Mar 31, 2026 | 1.94 Bn |
| Dec 31, 2025 | 2.14 Bn |
| Sep 30, 2025 | 800.07 Mn |
| Jun 30, 2025 | 1.51 Bn |
| Mar 31, 2025 | 1.51 Bn |
| Dec 31, 2024 | 1.51 Bn |
| Sep 30, 2024 | 1.50 Bn |
| Jun 30, 2024 | 1.50 Bn |
| Mar 31, 2024 | 1.50 Bn |
| Dec 31, 2023 | 1.50 Bn |
| Sep 30, 2023 | 1.50 Bn |
| Jun 30, 2023 | 1.50 Bn |
| Mar 31, 2023 | 1.49 Bn |
| Dec 31, 2022 | 1.51 Bn |
| Sep 30, 2022 | 1.50 Bn |
| Jun 30, 2022 | 1.15 Bn |
| Mar 31, 2022 | 788.10 Mn |
| Dec 31, 2021 | 787.26 Mn |
| Sep 30, 2021 | 786.45 Mn |